XACT ACE Robotics System Receives Expanded FDA Clearance For Ablation Procedures

Medtech Insight spoke with XACT Robotics’ executive chairman Harel Gadot about plans for the FDA-cleared ACE robotic system and its market opportunities.

Surgery
• Source: Shutterstock

After COVID-related setbacks, placements of XACT Robotics Ltd.'s ACE hands-free robotic-assisted device for use in percutaneous interventional procedures are gaining traction in the US.

Harel Gadot, XACT’s founder and executive chairman, told Medtech Insight that the company expects to sell six ACE Robotic Systems by the end of June, adding to the four systems sold since it was first cleared by the US Food and Drug Administration in 2019

More from Robotic Surgery

More from Surgery

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

Looking Back Towards The Future

 

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.

J&J Medtech’s FDA-Cleared DUALTO System Prepares For Future Use With OTTAVA Robotic Platform

 
• By 

DUALTO’s double-module option provides enhanced flexibility while cutting down on equipment clutter. Compared to traditional setups, the system reduces OR footprint by 46%, helping staff reclaim space and optimize surgical workflows.